Clinical trial
BAY43-9006 - Phase II in Advanced Breast Cancer
NCT00101400 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00101400 |
|---|---|
| Title | BAY43-9006 - Phase II in Advanced Breast Cancer |
| Official title | A Phase II Multicenter Uncontrolled Trial of BAY43-9006 in Subjects With Metastatic Breast Cancer. |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Breast Cancer |
| Intervention type | Drug |
| Interventions | Sorafenib (Nexavar, BAY43-9006) |
| Enrollment | 54 |
| Start date | Feb 1, 2004 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2008 |
| First posted | Jan 11, 2005 |
| Last update posted | Dec 13, 2013 |
| Countries | Germany, Italy |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: